unknown
Stage
About
Himalaya Therapeutics develops conditionally active biologics (CAB) therapies that selectively target tumor cells for safer and more potent cancer treatment, leveraging exclusive access to BioAtla’s CAB technology in China.
Explore Himalaya Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.